Trial · NCT06148792
A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria
NCT06148792, Phase 3, Recruiting, Menzies School of Health Research
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria. Trials, record NCT06148792. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06148792
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria
- NCT number
- NCT06148792
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 1,090 participants, estimated
- Lead sponsor
- Menzies School of Health Research
- Conditions
- Vivax Malaria
- Interventions
- Tafenoquine, Primaquine
- First posted
- 2023-11-28
- Last updated
- 2025-07-18
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The incidence risk of vivax parasitaemia | 4 months | The incidence risk (time to first event) of any P. vivax parasitaemia during the 4-month follow up period as determined by microscopy. * compared between TQRevised and the PQ7 (non-inferiority) * compared between TQRevised and TQStandard (superiority) |
| Secondary | The incidence risk of vivax parasitaemia | 4 months | The incidence risk (time to first event) of any P. vivax parasitaemia during the 4-month follow up period as determined by microscopy compared between TQStandard and PQ7 |
| Secondary | The incidence risk of symptomatic vivax parasitaemia | 4 months | The incidence risk (time to first event) of symptomatic P. vivax parasitaemia during the 4 months follow up period as determined by microscopy |
| Secondary | The incidence risk of vivax parasitaemia | 6 months | The incidence risk (time to first event) of any P. vivax parasitaemia at 6-month follow up as determined by microscopy |
| Secondary | The incidence risk of symptomatic vivax parasitaemia | 6 months | The incidence risk (time to first event) of symptomatic P. vivax parasitaemia at 6-month follow up as determined by microscopy |
| Secondary | The incidence rate of vivax parasitaemia | 6 months | The incidence rate (events per person-time) of any P. vivax parasitaemia during the 6 months follow up period as determined by microscopy |
| Secondary | The incidence rate of symptomatic vivax parasitaemia | 6 months | The incidence rate (events per person-time) of symptomatic P. vivax parasitaemia during the 6 months follow up period as determined by microscopy |
| Secondary | The incidence risk of anaemia | 7 and 14 days, 6 months | The incidence risk of developing severe anaemia (Hb \< 5g/dl) or moderate (5g/dl and \<7g/dl) anaemia within 7 and 14 days of starting treatment and/or requiring blood transfusion within the 6 months follow up period |
| Secondary | The incidence risk of an acute drop in Hb | 7 and 14 days | The incidence risk of an acute drop in Hb of \>25% to \<7g/dl within 7 and 14 days of starting treatment |
| Secondary | Adverse events | 42 days | The number and proportion of adverse and serious adverse events in each arm within 42 days after start of treatment |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06148792
GET https://conductscience.org/api/trials/v1/NCT06148792/registered